- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05378464
Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine & Pepinemab /Trastuzumab in Patients w/ Metastatic HER2+ Breast Cancer
Phase 1 Study of Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine and Pepinemab / Trastuzumab in Patients With Metastatic HER2-Positive Breast Cancer
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Patients with HER2-positive (HER2+) metastatic breast cancer will be treated with 6 weekly injections of dendritic cell (DC1) vaccines in combination with trastuzumab and pepinemab.
Investigators hypothesize these therapies will elicit CD4+ HER2 specific T cell responses. HER2 specific T cells will be expanded ex vivo which will be infused to patients subsequently following lymphodepletion therapy with cyclophosphamide. Trastuzumab and pepinemab will be given as maintenance in addition to booster DC1 vaccines.
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Kim Sprenger
- Phone Number: 813-745-0330
- Email: ICETClinicalTrialReferrals@moffitt.org
Study Locations
-
-
Florida
-
Tampa, Florida, United States, 33612
- Recruiting
- Moffitt Cancer Center
-
Principal Investigator:
- Heather Han, MD
-
Contact:
- Kim Sprenger
- Email: ICETClinicalTrialReferrals@moffitt.org
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Must have a histologically confirmed HER2 positive breast cancer and must be candidates for trastuzumab therapy as per current standard of care. Note: HER2 positive breast cancer is defined by tumor tissue HER2 overexpression and or tumor HER2 amplification per ASCO/CAP criteria.
- Patients will be eligible regardless of ER/PR status which will be determined per 2020 ASCO/CAP guideline and hormonal therapy will be allowed to continue for patients with ER/PR positive disease.
- Must have evaluable disease, defined as at least one lesion that can be accurately measured ≥ 10 mm by standard imaging techniques that can be include but not limited to CT, PET, PET/CT, MRI. Skeletal disease which is measurable by PET/CT or bone scan will also be allowed.
- Must have had disease progression while on trastuzumab for the treatment of HER2+ MBC and received no more than 3 lines of cytotoxic chemotherapy in the setting of metastatic disease.
- ECOG performance status 0 or 1.
- Must have normal organ and marrow function as defined in protocol within 14 days of registration.
- Left ventricular ejection fraction above institutional lower limit of normal (by echocardiogram or MUGA scan)
- Female patients of childbearing potential must agree to use dual methods of contraception and have a negative serum or urine pregnancy test at screening, and male patients must use an effective barrier method of contraception if sexually active with a female of child-bearing potential. Acceptable methods of contraception are condoms with contraceptive foam, oral, implantable or injectable contraceptives, contraceptive patch, intrauterine device, diaphragm with spermicidal gel, or a sexual partner who is surgically sterilized or post-menopausal. For both male and female patients, effective methods of contraception must be used throughout the study and for 3 months following the last dose. To be considered of not to be of childbearing potential, postmenopausal women must be amenorrheic for at least 12 months naturally (not in the setting of post chemotherapy) or patients must be surgically sterile.
- Must have the ability to understand and the willingness to sign a written informed consent prior to registration on study.
- Must have a life expectancy of at least 12 weeks.
Exclusion Criteria:
- Patients who have had chemotherapy or radiotherapy within 14 days prior to beginning protocol therapy.
- Patients may not be receiving any other investigational agents within 14 days or 5 half-lives (whichever is longer) prior to beginning protocol therapy.
- Patients with uncontrolled brain metastases or leptomeningeal disease
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
- Patients with active autoimmune disease or history of autoimmune disease that might recur, which may affect vital organ function or require immune suppressive treatment including chronic prolonged systemic corticosteroids (defined as corticosteroid use of duration one month or greater), should be excluded.
- Female patients who are pregnant or nursing are not eligible.
- Second invasive malignancy requiring active treatment
- Known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS) is not permitted.
- Any known positive test for Hepatitis B or Hepatitis C virus indicating acute or chronic infection is not permitted.
- Patients who have received a live attenuated vaccine ≤30 days of registration are not eligible.
- Patients not able to comply with the treatment schedule and study procedures for any reason are not eligible.
- Patients previously treated with any form of adoptive cell transfer therapy.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: T-Cell therapy dose level 1
Participants will begin treatment with pepinemab and trastuzumab, and begin DC1 vaccines.
After 6 weeks of DC1 vaccines, blood will be collected for t-cell therapy, and patients will then be treated with IL-15 Expanded HER2 specific CD4+ Th1 cell 0.5.0-2.5 x 10^8, IL-7 and Expanded HER2 specific CD4+ Th1 cell 0.5.0-2.5 x 10^8.
|
Participants will receive a DC1 vaccine injection at 1.0-2.0
x 10^7 cells, either to groin lymph notes or to tumor if accessible once a week for 3 weeks on days 1, 8 and 15.
Participants will receive DC1 vaccine boosters every 3 weeks x 3.
Participants will receive trastuzumab 8 mg/kg by IV week 1, then 6 mg/kg by IV beginning week 4 and continuing every 3 weeks until disease progression or intolerable toxicity.
Other Names:
Participants will receive pepinemab 20 mg/kg by IV beginning week 1 and continuing every 3 weeks until disease progression or intolerable toxicity.
Participants will receive IL-15 expanded CD4 T cells infusion by IV Day 1 at week 8, 2 weeks from last DC1 vaccine, and IL-7 expanded CD4 T cells infusion IV at week 8 day 8.
|
Experimental: T-Cell therapy dose level 2
Participants will begin treatment with pepinemab and trastuzumab, and begin DC1 vaccines.
After 6 weeks of DC1 vaccines, blood will be collected for t-cell therapy, and patients will then be treated with IL-15 Expanded HER2 specific CD4+ Th1 cell .25-1.2 x 10^9, IL-7 and Expanded HER2 specific CD4+ Th1 cell .25-1.2 x 10^9.
|
Participants will receive a DC1 vaccine injection at 1.0-2.0
x 10^7 cells, either to groin lymph notes or to tumor if accessible once a week for 3 weeks on days 1, 8 and 15.
Participants will receive DC1 vaccine boosters every 3 weeks x 3.
Participants will receive trastuzumab 8 mg/kg by IV week 1, then 6 mg/kg by IV beginning week 4 and continuing every 3 weeks until disease progression or intolerable toxicity.
Other Names:
Participants will receive pepinemab 20 mg/kg by IV beginning week 1 and continuing every 3 weeks until disease progression or intolerable toxicity.
Participants will receive IL-15 expanded CD4 T cells infusion by IV Day 1 at week 8, 2 weeks from last DC1 vaccine, and IL-7 expanded CD4 T cells infusion IV at week 8 day 8.
|
Experimental: T-Cell therapy dose level 3
Participants will begin treatment with pepinemab and trastuzumab, and begin DC1 vaccines.
After 6 weeks of DC1 vaccines, blood will be collected for t-cell therapy, and patients will then be treated with IL-15 Expanded HER2 specific CD4+ Th1 cell .5-2.5 x 10^9, IL-7 and Expanded HER2 specific CD4+ Th1 cell .5-2.5 x 10^9.
|
Participants will receive a DC1 vaccine injection at 1.0-2.0
x 10^7 cells, either to groin lymph notes or to tumor if accessible once a week for 3 weeks on days 1, 8 and 15.
Participants will receive DC1 vaccine boosters every 3 weeks x 3.
Participants will receive trastuzumab 8 mg/kg by IV week 1, then 6 mg/kg by IV beginning week 4 and continuing every 3 weeks until disease progression or intolerable toxicity.
Other Names:
Participants will receive pepinemab 20 mg/kg by IV beginning week 1 and continuing every 3 weeks until disease progression or intolerable toxicity.
Participants will receive IL-15 expanded CD4 T cells infusion by IV Day 1 at week 8, 2 weeks from last DC1 vaccine, and IL-7 expanded CD4 T cells infusion IV at week 8 day 8.
|
Experimental: T Cell therapy dose expansion
Participants will begin treatment with pepinemab and trastuzumab, and begin DC1 vaccines.
After 6 weeks of DC1 vaccines, blood will be collected for t-cell therapy, and patients will then be treated with CD4 treated t-cells at the maximum tolerated dose determined.
|
Participants will receive a DC1 vaccine injection at 1.0-2.0
x 10^7 cells, either to groin lymph notes or to tumor if accessible once a week for 3 weeks on days 1, 8 and 15.
Participants will receive DC1 vaccine boosters every 3 weeks x 3.
Participants will receive trastuzumab 8 mg/kg by IV week 1, then 6 mg/kg by IV beginning week 4 and continuing every 3 weeks until disease progression or intolerable toxicity.
Other Names:
Participants will receive pepinemab 20 mg/kg by IV beginning week 1 and continuing every 3 weeks until disease progression or intolerable toxicity.
Participants will receive IL-15 expanded CD4 T cells infusion by IV Day 1 at week 8, 2 weeks from last DC1 vaccine, and IL-7 expanded CD4 T cells infusion IV at week 8 day 8.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum Tolerated Dose (MTD) of expanded CD4 T cells
Time Frame: Up to 6 months
|
MTD of expanded CD4 T cells after treatment with DC1 vaccines and trastuzumab/pepinemab.
|
Up to 6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall Response Rate (ORR)
Time Frame: Up to 6 months
|
ORR according to RECIST criteria v1.1 and iRECIST of treatment DC1 vaccines and pepinemab/trastuzumab
|
Up to 6 months
|
Clinical Benefit Rate (CBR) of DC1 vaccines and pepinemab/trastuzumab
Time Frame: at 6 months
|
To assess the 6-month clinical benefit rate (CBR) according to RECIST criteria v. 1.1 of treatment with DC1 vaccines and pepinemab/trastuzumab
|
at 6 months
|
Clinical Benefit Rate (CBR) of expanded CD4 T Cells
Time Frame: at 6 months
|
To assess the 6-month CBR according to RECIST criteria v. 1.1 of treatment with expanded CD4+ T cells following DC1 vaccines and pepinemab/trastuzumab.
|
at 6 months
|
Progression Free Survival (PFS)
Time Frame: Up to 36 months
|
PFS is defined as the length of time from start of treatment to progression or death.
|
Up to 36 months
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Heather Han, MD, Moffitt Cancer Center
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- MCC-21378
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HER2-positive Breast Cancer
-
Mersana TherapeuticsRecruitingHER2-positive Breast Cancer | HER2-positive Gastric Cancer | HER2-positive Non-Small Cell Lung Cancer | HER2-positive Colorectal Cancer | HER2-positive Tumors | HER2 Low Breast CancerUnited States
-
QuantumLeap Healthcare CollaborativeRecruitingSolid Tumor | Metastatic Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | HER2-positive Breast Cancer | Solid Tumor, Adult | Solid Carcinoma | HER2-positive Metastatic Breast Cancer | Progesterone Receptor-positive Breast Cancer | HER2-negative Breast Cancer | Estrogen Receptor Positive... and other conditionsUnited States
-
MacroGenicsApproved for marketingHER2-positive Breast Cancer | HER2-positive Carcinoma
-
Spanish Breast Cancer Research GroupSeagen Inc.RecruitingHER2-positive Metastatic Breast Cancer | Locally Advanced HER2 Positive Breast CarcinomaSpain
-
Cancer Trials IrelandCompletedBreast Cancer | HER2 Positive Breast Cancer | HER2 Negative Breast CancerIreland
-
University of ArizonaPfizerCompletedBreast Cancer | Metastatic Breast Cancer | HER2-positive Breast Cancer | Recurrent Breast Cancer | HER2 Positive Breast Carcinoma | Breast Cancer StageUnited States
-
Enliven TherapeuticsRecruitingColorectal Cancer | HER2-positive Breast Cancer | HER2-positive Gastric Cancer | HER2 Amplification | HER2 Positive Solid TumorsUnited States
-
Daiichi SankyoRecruitingBreast Cancer | Advanced Cancer | HER2-positive Breast Cancer | HER2-low Breast CancerChina
-
Ruth O'ReganUniversity of Rochester; Puma Biotechnology, Inc.RecruitingBreast Cancer | HER2-positive Breast Cancer | ER Positive Breast Cancer | PR-Positive Breast CancerUnited States
-
BioInvent International ABActive, not recruitingHER2-positive Breast Cancer | HER2-positive Gastric Cancer | Metastatic Gastric Adenocarcinoma | Metastatic Gastroesophageal Junction Adenocarcinoma | HER2-positive Metastatic Breast CancerSpain, United Kingdom, Germany
Clinical Trials on Dendritic Cell (DC1) Vaccine
-
Hospital Clinic of BarcelonaCompleted
-
H. Lee Moffitt Cancer Center and Research InstituteUnited States Department of DefenseActive, not recruitingBreast Cancer, Male | HER2-positive Breast Cancer | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Female | Breast Cancer Stage III | Residual Disease | HER2 Positive Breast CarcinomaUnited States
-
H. Lee Moffitt Cancer Center and Research InstituteUnited States Department of DefenseActive, not recruitingBreast Cancer | Breast Cancer, Male | HER2-positive Breast Cancer | Invasive Breast Cancer | Stage II Breast Cancer | Breast Cancer Female | HER2 Positive Breast Carcinoma | Stage III Breast CancerUnited States
-
Jan WalewskiCompletedLymphoma | Multiple Myeloma and Plasma Cell NeoplasmPoland
-
Roswell Park Cancer InstituteUniversity of PittsburghCompletedProstate Cancer | Prostate Neoplasms | Cancer of the Prostate | Neoplasms, Prostate | Prostatic Cancer | Neoplasms, Prostatic | Cancer of ProstateUnited States
-
H. Lee Moffitt Cancer Center and Research InstituteUnited States Department of DefenseRecruitingTriple Negative Breast Cancer | HER2-positive Breast Cancer | Leptomeningeal DiseaseUnited States
-
Oslo University HospitalActive, not recruiting
-
University of Maryland, BaltimoreWithdrawnSquamous Cell Carcinoma of Head and NeckUnited States
-
Memorial Sloan Kettering Cancer CenterNational Cancer Institute (NCI); National Institutes of Health (NIH); Rockefeller...CompletedMelanomaUnited States
-
University of PittsburghCompletedSezary Syndrome | Cutaneous T-cell LymphomaUnited States